Patents by Inventor Pauline Ting
Pauline Ting has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 11498923Abstract: Disclosed are compounds having the structure of Formula I, or a pharmaceutically acceptable salt of any thereof: wherein: “Z” and R1 are defined herein, which compounds are believed suitable for use in selectively antagonizing the A2a receptors, for example, those found in high density in the basal ganglia. Such compounds and pharmaceutical formulations are believed to be useful in treatment or management of neurodegenerative diseases, for example, Parkinson's disease, or movement disorders arising from use of certain medications used in the treatment or management of Parkinson's disease.Type: GrantFiled: December 10, 2018Date of Patent: November 15, 2022Assignee: Merck Sharp & Dohme LLCInventors: Yeon-Hee Lim, Gioconda V. Gallo-Etienne, Joseph Michael Kelly, Michael Berlin, Pauline Ting, Hongwu Wang
-
Publication number: 20210053973Abstract: Disclosed are compounds having the structure of Formula I, or a pharmaceutically acceptable salt of any thereof: wherein: “Z” and R1 are defined herein, which compounds are believed suitable for use in selectively antagonizing the A2a receptors, for example, those found in high density in the basal ganglia. Such compounds and pharmaceutical formulations are believed to be useful in treatment or management of neurodegenerative diseases, for example, Parkinson's disease, or movement disorders arising from use of certain medications used in the treatment or management of Parkinson's disease.Type: ApplicationFiled: December 10, 2018Publication date: February 25, 2021Applicant: Merck Sharp & Dohme Corp.Inventors: Amjad ALI, Yeon-Hee LIM, Gioconda V. GALLO-ETIENNE, Joseph Michael KELLY, Michael BERLIN, Pauline TING, Jayaram R. TAGAT, Dong XIAO, Rongze KUANG, Heping WU, Hongwu WANG
-
Patent number: 10688082Abstract: Disclosed are compounds having the structure of Formula I, or a pharmaceutically acceptable salt of any thereof, wherein: “Z”, R1 and R2 are defined herein, which compounds are believed suitable for use in selectively antagonizing the A2a receptors, for example, those found in high density in the basal ganglia. Such compounds and pharmaceutical formulations are believed to be useful in treatment or management of neurodegenerative diseases, for example, Parkinson's disease, or movement disorders arising from use of certain medications used in the treatment or management of Parkinson's disease.Type: GrantFiled: June 6, 2016Date of Patent: June 23, 2020Assignee: Merck Sharp & Dohme Corp.Inventors: Junying Zheng, Walter Won, Michael Berlin, Pauline Ting, Guoqing Li, Dong Xiao, Hongwu Wang, Robert Aslanian
-
Patent number: 10472347Abstract: Disclosed are compounds of Formula A and Formula A-1, or a salt thereof, and pharmaceutical formulations (pharmaceutical compositions) comprising those compounds, or a salt thereof; wherein “R1”, “RA-1”, “R2”, “R3”, and “Het” are defined herein above, which compounds are believed suitable for use in selectively antagonizing the A2a receptors, for example, those found in high density in the basal ganglia. Such compounds and pharmaceutical formulations are believed to be useful in treatment or management of neurodegenerative diseases, for example, Parkinson's disease, or movement disorders arising from use of certain medications used in the treatment or management of Parkinson's disease.Type: GrantFiled: November 13, 2015Date of Patent: November 12, 2019Assignee: Merck Sharp & Dohme Corp.Inventors: Rongze Kuang, Pauline Ting, Amjad Ali, Heping Wu, Michael Berlin, Andrew Stamford, Hongwu Wang, Gang Zhou, David Kim, Qiaolin Deng, Yeon-Hee Lim, Younong Yu
-
Publication number: 20180327385Abstract: Disclosed are compounds of Formula A and Formula A-1, or a salt thereof, and pharmaceutical formulations (pharmaceutical compositions) comprising those compounds, or a salt thereof; wherein “R1”, “RA-1”, “R2”, “R3”, and “Het” are defined herein above, which compounds are believed suitable for use in selectively antagonizing the A2a receptors, for example, those found in high density in the basal ganglia. Such compounds and pharmaceutical formulations are believed to be useful in treatment or management of neurodegenerative diseases, for example, Parkinson's disease, or movement disorders arising from use of certain medications used in the treatment or management of Parkinson's disease.Type: ApplicationFiled: November 13, 2015Publication date: November 15, 2018Applicant: Merck Sharp & Dohme Corp.Inventors: Rongze KUANG, Pauline Ting, Amjad Ali, Heping Wu, Michael Berlin, Andrew Stamford, Hongwu Wang, Gang Zhou, David Kim, Qiaolin Deng, Yeon-Hee Lim, Younong Yu
-
Publication number: 20180193314Abstract: Disclosed are compounds having the structure of Formula I, or a pharmaceutically acceptable salt of any thereof, wherein: “Z”, R1 and R2 are defined herein, which compounds are believed suitable for use in selectively antagonizing the A2a receptors, for example, those found in high density in the basal ganglia. Such compounds and pharmaceutical formulations are believed to be useful in treatment or management of neurodegenerative diseases, for example, Parkinson's disease, or movement disorders arising from use of certain medications used in the treatment or management of Parkinson's disease.Type: ApplicationFiled: June 6, 2016Publication date: July 12, 2018Applicant: Merck Sharp & Dohme Corp.Inventors: Junying Zheng, Walter Won, Michael Berlin, Pauline Ting, Guoqing Li, Dong Xiao, Hongwu Wang, Robert Aslanian
-
Patent number: 10011615Abstract: Disclosed are compounds of Formula G1: where “RG3”. “Rd1” to “Rd4”, “n”, “m”, “p”, “W”, “X”, “Y”, and “Z” are defined herein, which compounds are antagonists of A2A receptor. Disclosed herein also are uses of the compounds described herein as antagonists of the A2A receptor in the potential treatment or prevention of neurological disorders and diseases in which A2A receptors are involved. Disclosed herein also are pharmaceutical compositions comprising these compounds and uses of these pharmaceutical compositions.Type: GrantFiled: February 2, 2017Date of Patent: July 3, 2018Assignee: Merck Sharp & Dohme Corp.Inventors: Amjad Ali, Michael Man-Chu Lo, Yeon-Hee Lim, Andrew Stamford, Rongze Kuang, Paul Tempest, Younong Yu, Xianhai Huang, Timothy J. Henderson, Jae-Hun Kim, Christopher Boyce, Pauline Ting, Junying Zheng, Edward Metzger, Nicolas Zorn, Dong Xiao, Gioconda V. Gallo, Walter Won, Heping Wu, Qiaolin Deng
-
Publication number: 20170197991Abstract: Disclosed are compounds of Formula G1: where “RG3”. “Rd1” to “Rd4”, “n”, “m”, “p”, “W”, “X”, “Y”, and “Z” are defined herein, which compounds are antagonists of A2A receptor. Disclosed herein also are uses of the compounds described herein as antagonists of the A2A receptor in the potential treatment or prevention of neurological disorders and diseases in which A2A receptors are involved. Disclosed herein also are pharmaceutical compositions comprising these compounds and uses of these pharmaceutical compositions.Type: ApplicationFiled: February 2, 2017Publication date: July 13, 2017Applicant: Merck Sharp & Dohme Corp.Inventors: Amjad Ali, Michael Man-Chu Lo, Yeon-Hee Lim, Andrew Stamford, Rongze Kuang, Paul Tempest, Younong Yu, Xianhai Huang, Timothy J. Henderson, Jae-Hun Kim, Christopher Boyce, Pauline Ting, Junying Zheng, Edward Metzger, Nicolas Zorn, Dong Xiao, Gioconda V. Gallo, Walter Won, Heping Wu, Qiaolin Deng
-
Patent number: 9676780Abstract: Disclosed are compounds of Formula A: (structurally represented) where “RG1”, “RG2a”, “RG4”, “RG5”, “MG1”, “n” and “m” are defined herein which compounds are antagonists of A2A receptor. Disclosed herein also are uses of the compounds described herein as antagonists of the A2a receptor in the potential treatment or prevention of neurological disorders and diseases in which A2A receptors are involved. Disclosed herein also are pharmaceutical compositions comprising these compounds and uses of these pharmaceutical compositions.Type: GrantFiled: December 20, 2013Date of Patent: June 13, 2017Assignee: Merck Sharp & Dohme Corp.Inventors: Amjad Ali, Michael Man-Chu Lo, Yeon-Hee Lim, Andrew Stamford, Rongze Kuang, Paul Tempest, Younong Yu, Michael Berlin, Pauline Ting, Gang Zhou, Tao Yu, Christopher Boyce, Joseph Michael Kelly, Jayaram R. Tagat, Junying Zheng, Xianhai Huang, Wei Zhou, Jae-Hun Kim, Nicolas Zorn, Dong Xiao, Gioconda V. Gallo, Walter Won, Heping Wu, Rajan Anand, Qiaolin Deng
-
Publication number: 20160194330Abstract: Disclosed are compounds of Formula A: (structurally represented) where “RG1”, “RG2a”, “RG4”, “RG5”, “MG1”, “n” and “m” are defined herein which compounds are antagonists of A2A receptor. Disclosed herein also are uses of the compounds described herein as antagonists of the A2a receptor in the potential treatment or prevention of neurological disorders and diseases in which A2A receptors are involved. Disclosed herein also are pharmaceutical compositions comprising these compounds and uses of these pharmaceutical compositions.Type: ApplicationFiled: December 20, 2013Publication date: July 7, 2016Applicant: Merck Sharp & Dohme Corp.Inventors: Amjad Ali, Michael Man-Chu Lo, Yeon-Hee Lim, Andrew Stamford, Rongze Kuang, Paul Tempest, Younong Yu, Michael Berlin, Pauline Ting, Gang Zhou, Tao Yu, Christopher Boyce, Joseph Michael Kelly, Jayaram R. Tagat, Junying Zheng, Xianhai Huang, Wei Zhou, Jae-Hun Kim, Nicolas Zorn, Dong Xiao, Gioconda V. Gallo, Walter Won, Heping Wu, Rajan Anand, Qiaolin Deng
-
Publication number: 20150361098Abstract: Disclosed are compounds of Formula G1 (structurally represented): where “RG3” “Rd1” to “Rd4”, “n”, “m”, “p”, “W”, “X”, “Y”, and “Z” are defined herein which compounds are antagonists of A2A receptor. Disclosed herein also are uses of the compounds described herein as antagonists of the A2a receptor in the potential treatment or prevention of neurological disorders and diseases in which A2A receptors are involved. Disclosed herein also are pharmaceutical compositions comprising these compounds and uses of these pharmaceutical compositions.Type: ApplicationFiled: December 20, 2013Publication date: December 17, 2015Applicant: Merck Sharp & Dohme Corp.Inventors: Amjad Ali, Michael Man-Chu Lo, Yeon-Hee Lim, Andrew Stamford, Rongze Kuang, Paul Tempest, Younong Yu, Xianhai Huang, Timothy J. Henderson, Jae-Hun Kim, Christopher Boyce, Pauline Ting, Junying Zheng, Edward Metzger, Nicolas Zorn, Dong Xiao, Gioconda V. Gallo, Walter Won, Heping Wu, Qiaolin Deng
-
Publication number: 20080027101Abstract: The present invention relates to the compound of the formula To methods of treating upper and lower obstructive airway diseases using said compound, to formulations comprising it, and to polymorphs and processes of synthesis of the polymorphic forms.Type: ApplicationFiled: July 10, 2007Publication date: January 31, 2008Inventors: Pauline Ting, Joe Lee, Kung-I Feng, Michael Reeder, Scott Trzaska, Man Zhu, Chen Mao, Dimitar Filipov, Dimitrios Zarkadas
-
Publication number: 20070010513Abstract: Disclosed are compounds of the formula or a pharmaceutically acceptable salt thereof, wherein: M1 and M3 are CH or N; M2 is CH, CF or N; Y is —C(?O)—, —C(?S)—, —(CH2)q—, —C(?NOR7)— or —SO1-2—; Z is a bond or optionally substituted alkylene or alkenylene; R1 is H, alkyl, alkenyl, or optionally substituted cycloalkyl, aryl, heteroaryl, heterocycloalkyl or a group of the formula: where ring A is a monoheteroaryl ring; R1 is optionally substituted alkyl, alkenyl, aryl, heteroaryl, cycloalkyl or heterocycloalkyl; and the remaining variables are as defined in the specification; compositions and methods of treating allergy-induced airway responses, congestion, obesity, metabolic syndrome nonalcoholic fatty liver disease, hepatic steatosis, nonalcoholic steatohepatitis, cirrhosis, hepatacellular carcinoma or cognition deficit disorders using said compounds, alone or in combination with other agents.Type: ApplicationFiled: June 19, 2006Publication date: January 11, 2007Inventors: Robert Aslanian, Michael Berlin, Ying Huang, Kevin McCormick, Mwangi Mutahi, Neng-Yang Shih, Pauline Ting, Wing Tom, Junying Zheng
-
Publication number: 20060252778Abstract: This invention relates to compounds of the Formula (I): or a pharmaceutically acceptable salt, solvate or isomer thereof, which can be useful for the treatment of diseases or conditions mediated by MMPs, ADAMs, TACE, TNF-? or combinations thereof.Type: ApplicationFiled: June 1, 2005Publication date: November 9, 2006Inventors: Zhuyan Guo, Peter Orth, Zhaoning Zhu, Robert Mazzola, Tin-Yau Chan, Henry Vaccaro, Brian McKittrick, Joseph Kozlowski, Brian Lavey, Guowei Zhou, Sunil Paliwal, Shing-Chun Wong, Neng-Yang Shih, Pauline Ting, Kristin Rosner, Gerald Shipps, M. Siddiqui, David Belanger, Chaoyang Dai, Dansu Li, Vinay Girijavallabhan, Janeta Popovici-Muller, Wensheng Yu, Lianyun Zhao
-
Publication number: 20060106062Abstract: The invention claims compounds of the formula wherein is a 5-membered heteroaryl; X is S or O; R1 is H, alkyl, cycloalkyl, cylcoalkylalkyl-, —CH2F, —CHF2, —CF3, —C(O)alkyl or —C(O)NR18R19; R3 and R4H, alkyl, hydroxyalkyl or —C(O)Oalkyl; R5 and R6 are H, alkyl, hydroxyalkyl, alkoxyalkyl, mercaptoalkyl, —CH2F, —CHF2, —CF3, —C(O)OH or —C(O)Oalkyl; R7 is H, alkyl, alkenyl, hydroxyalkyl, cycloalkyl, alkoxyalkyl, aminoalkyl, (R17-phenyl)alkyl or —CH2—C(O)—O-alkyl; and R8 comprises alkyl, heteroaryl, phenyl or cycloalkyl, or heterocycloalkyl, all optionally substituted, or a cycloalkyl- or heterocycloalkyl-substituted amide; or R7 and R8 and the nitrogen to which they are attached together form an optionally substituted ring; and the remaining variables are as defined in the specification. Also claimed are pharmaceutical compositions, the use of the compounds as PDE4 inhibitors, and combinations with other actives.Type: ApplicationFiled: May 16, 2005Publication date: May 18, 2006Inventors: Rongze Kuang, David Blythin, Neng-Yang Shih, Ho-Jane Shue, Xiao Chen, Jianhua Cao, Danlin Gu, Ying Huang, John Schwerdt, Pauline Ting, Shing-Chun Wong, Li Xiao
-
Publication number: 20050182095Abstract: The use of CCR3 antagonists of the formula I or a pharmaceutically acceptable salt thereof for the treatment of asthma is disclosed, as well as novel compounds of the formula II, pharmaceutical compositions comprising them, and their use in the treatment of asthma, wherein R, Ra, X, Xa, R1, R2, R2a, R14, R14a, R16 and n are as defined in the specification.Type: ApplicationFiled: February 2, 2005Publication date: August 18, 2005Inventors: Pauline Ting, Jianhua Cao, Youhao Dong, Eric Gilbert, Ying Huang, Joseph Kelly, Stuart McCombie, Neng-Yang Shih
-
Publication number: 20050113383Abstract: Disclosed are novel compounds of the formula Also disclosed are pharmaceutical compositions comprising the compounds of Formula I. Also disclosed are methods of treating various diseases or conditions, such as, for example, allergy, allergy-induced airway responses, and congestion (e.g., nasal congestion) using the compounds of Formula I. Also disclosed are methods of treating various diseases or conditions, such as, for example, allergy, allergy-induced airway responses, and congestion (e.g., nasal congestion) using the compounds of Formula I in combination with a H1 receptor antagonist.Type: ApplicationFiled: October 27, 2004Publication date: May 26, 2005Inventors: Stuart Rosenblum, Qingbei Zeng, Mwangi Mutahi, Robert Aslanian, Pauline Ting, Neng-Yang Shih, Daniel Solomon, Jianhua Cao, Henry Vaccaro, Kevin McCormick, John Baldwin, Ge Li